medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2017-18-102-106medsovet-2040Research ArticleРациональная фармакотерапияRational pharmacotherapyКОМПЛЕКСНЫЙ ПОДХОД К ТЕРАПИИ ОСТРЫХ И ХРОНИЧЕСКИХ ЗАБОЛЕВАНИЙ ОРГАНОВ ДЫХАНИЯCOMPLEX APPROACH TO THERAPY OF ACUTE AND CHRONIC DIEASES OF RESPIRATORY ORGANSВизельА. А.ViselA. A.

д.м.н., профессор

MD, Prof.

ВизельИ. Ю.ViselI. Y.

к.м.н.

PhD in medicine

ГизатуллинаЭ. Д.GizatullinaE. D.

к.м.н

PhD in medicine

Казанский государственный медицинский университет Минздрава РоссииРоссияKazan State Medical University of the Ministry of Health of RussiaRussian Federation201703112017018102106Copyright © Визель А.А., Визель И.Ю., Гизатуллина Э.Д., 20172017Визель А.А., Визель И.Ю., Гизатуллина Э.Д.Visel A.A., Visel I.Y., Gizatullina E.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2040

Представлен обзор зарубежной и отечественной литературы, посвященной применению фитопрепарата Миртол, который представляет собой оригинальный растительный комплекс, стандартизированный по содержанию трех компонентов: d-лимонена, 1,8-цинеола, α-пинена. Клиническая эффективность Миртола стандартизированного была доказана в лечении острого и хронического риносинусита, острого и хронического бронхита и хронической обструктивной болезни легких (ХОБЛ). Исследования показали, что препарат обладает широким фармакодинамическим профилем действия (муколитический, секретолитический, секретомоторный, антиоксидантный, противовоспалительный и антибактериальный эффекты) при высоком уровне безопасности.

 

A review of the foreign and Russian literature devoted to application of the herbal medicine Myrtol standardized, an original vegetative complex standardized by the content of three components: d-limonen, 1,8-cyneol, α-pinene. The clinical effectiveness of the standardized Myrtol was proved in the therapy of acute and chronic rhinosinusitis, acute and chronic bronchitis and chronic obstructive lung disease (COPD). The studies showed that the drug has a wide pharmacodynamic profile of action (mycolytic, secretolytic, secretomotor, antioxidant, anti-inflammatory and antibacterial effects) with high safety profie.

 

Миртол стандартизированныйГелоМиртол®ГелоМиртол® фортефитопрепаратсинуситриносинуситбронхитхроническая обструктивная болезнь легкихMyrtol standardizedGeloMyrtol®GeloMyrtol® Forteherbal medicinesinusitisrhinosinusitisbronchitischronic obstructive lung diseaseReferencesЧучалин А.Г., Авдеев С.Н., Айсанов З.Р., Белевский А.С., Лещенко И.В., Мещерякова Н.Н., Овчаренко С.И., Шмелёв Е.И. Российское респираторное общество: Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. Пульмонология, 2014, 3: 16-36.Чучалин А.Г., Авдеев С.Н., Айсанов З.Р., Белевский А.С., Лещенко И.В., Мещерякова Н.Н., Овчаренко С.И., Шмелёв Е.И. Российское респираторное общество: Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. Пульмонология, 2014, 3: 16-36.Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (GOLD): 2017 report 2017: 123 p. www.coldcopd.prg.Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (GOLD): 2017 report 2017: 123 p. www.coldcopd.prg.Behrbohm H, Kaschke O, Sydow K. Effect of the phytogenic secretolytic drug Gelomyrtol forte on mucociliary clearance of the maxillary sinus. Laryngorhinootologie, 1995, 74: 733-737.Behrbohm H, Kaschke O, Sydow K. Effect of the phytogenic secretolytic drug Gelomyrtol forte on mucociliary clearance of the maxillary sinus. Laryngorhinootologie, 1995, 74: 733-737.Zimmermann T, Seiberling M, Thomann P, Karabelnik D. The relative bioavailability and pharmacokinetics of standardized myrtol. Arzneimittelforschung. 1995; 45: 1198–1201.Zimmermann T, Seiberling M, Thomann P, Karabelnik D. The relative bioavailability and pharmacokinetics of standardized myrtol. Arzneimittelforschung. 1995; 45: 1198–1201.Grassmann J, Hipelli S, Dornisch K, Rohnert U, Beuscher N, Elstner EF. Antioxidant Properties Of Essential Oils. Possible explanations for their anti-inflammatory effects. Arzneimittelforschung, 2000, 50(02): 135-139.Grassmann J, Hipelli S, Dornisch K, Rohnert U, Beuscher N, Elstner EF. Antioxidant Properties Of Essential Oils. Possible explanations for their anti-inflammatory effects. Arzneimittelforschung, 2000, 50(02): 135-139.Beuscher N, Keitzmann M, Bien E, Champeroux P. Interference of Myrtol standardized with inflammatory and allergic mediators. Arzneimittelforschung, 1998, (48): 985-989.Beuscher N, Keitzmann M, Bien E, Champeroux P. Interference of Myrtol standardized with inflammatory and allergic mediators. Arzneimittelforschung, 1998, (48): 985-989.Beeh KM, Beier J, Candler H, Wittig T. Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype – a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial. Int. J. Chron. Obstruct. Pulmon. Dis., 2016, 11: 2877-2884.Beeh KM, Beier J, Candler H, Wittig T. Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype – a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial. Int. J. Chron. Obstruct. Pulmon. Dis., 2016, 11: 2877-2884.Federspil P, Wulkow R, Zimmermann T. Effects of standardized Myrtol in therapy of acute sinusitis – Results of a double-blind, randomized multicenter study compared with placebo. Laryngorhinootologie, 1997, 76: 23–27.Federspil P, Wulkow R, Zimmermann T. Effects of standardized Myrtol in therapy of acute sinusitis – Results of a double-blind, randomized multicenter study compared with placebo. Laryngorhinootologie, 1997, 76: 23–27.Виттиг Т. Миртол стандартизированный. Клиническая документация, Россия, 2009, 1-е издание, ISBN 3-8796-071-6: 22-44.Виттиг Т. Миртол стандартизированный. Клиническая документация, Россия, 2009, 1-е издание, ISBN 3-8796-071-6: 22-44.Lai Y, Dilidaer D, Chen B, Xu G, Shi J, Lee RJ, Cohen NA. In vitro studies of a distillate of rectified essential oils on sinonasal components of mucociliary clearance. American journal of rhinology and allergy, 2014, 28(3): 244-248.Lai Y, Dilidaer D, Chen B, Xu G, Shi J, Lee RJ, Cohen NA. In vitro studies of a distillate of rectified essential oils on sinonasal components of mucociliary clearance. American journal of rhinology and allergy, 2014, 28(3): 244-248.Christoph F, Kaulfers P, Stahl-Biskup E. In vitro Evaluation of the Antibacterial Activity of -Triketones Admixed to Melaleuca Oils. Planta Med, 2001, 67(08): 768-771.Christoph F, Kaulfers P, Stahl-Biskup E. In vitro Evaluation of the Antibacterial Activity of -Triketones Admixed to Melaleuca Oils. Planta Med, 2001, 67(08): 768-771.De Mey C, Riechelmann H. A Multi-centre, randomised, placebo-controlled, double-blind, repeateddose, parallel group study to assess the efficacy and tolerability of Myrtol in patients with chronic sinusitis. P9806GF. Köhne-Volland R. Addendum zur Konfirmatorischen Datenanalyse, Myrtol Standardisiert Dokumentation. 2008 German.De Mey C, Riechelmann H. A Multi-centre, randomised, placebo-controlled, double-blind, repeateddose, parallel group study to assess the efficacy and tolerability of Myrtol in patients with chronic sinusitis. P9806GF. Köhne-Volland R. Addendum zur Konfirmatorischen Datenanalyse, Myrtol Standardisiert Dokumentation. 2008 German.Matthys H, de Mey C, Carls C, Rys A, Geib A, Wittig T. Efficacy and tolerability of myrtol standardized in acute bronchitis A multi-centre, randomised, double-blind, placebo-controlled parallel group clinical trial vs cefuroxime and ambroxol. Arzneimittelforschung, 2000, 50: 700–711.Matthys H, de Mey C, Carls C, Rys A, Geib A, Wittig T. Efficacy and tolerability of myrtol standardized in acute bronchitis A multi-centre, randomised, double-blind, placebo-controlled parallel group clinical trial vs cefuroxime and ambroxol. Arzneimittelforschung, 2000, 50: 700–711.Gillissen A, Wittig T, Ehmen M, Krezdorn HG, de Mey C. A multi-centre, randomised, double-blind, placebo-controlled clinical trial on the efficacy and tolerability of GeloMyrtol® forte in acute bronchitis. Drug Res (Stuttg), 2013, 63: 19–27.Gillissen A, Wittig T, Ehmen M, Krezdorn HG, de Mey C. A multi-centre, randomised, double-blind, placebo-controlled clinical trial on the efficacy and tolerability of GeloMyrtol® forte in acute bronchitis. Drug Res (Stuttg), 2013, 63: 19–27.Meister R, Wittig T, Beuscher N, de Mey C. Efficacy and tolerability of myrtol standardized in longterm treatment of chronic bronchitis. A double-blind, placebo-controlled study Study Group Investigators. Arzneimittelforschung, 1999, 49: 351–358.Meister R, Wittig T, Beuscher N, de Mey C. Efficacy and tolerability of myrtol standardized in longterm treatment of chronic bronchitis. A double-blind, placebo-controlled study Study Group Investigators. Arzneimittelforschung, 1999, 49: 351–358.Poole P, Chong J, Cates CJ. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2015, 7: CD001287. doi: 10.1002/14651858.CD001287.pub5.Poole P, Chong J, Cates CJ. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2015, 7: CD001287. doi: 10.1002/14651858.CD001287.pub5.Beeh KM, Beier J, Candler H, Wittig T. Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype – a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial. Int. J. Chron. Obstruct. Pulmon. Dis., 2016, 11: 2877-2884.Beeh KM, Beier J, Candler H, Wittig T. Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype – a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial. Int. J. Chron. Obstruct. Pulmon. Dis., 2016, 11: 2877-2884.Rantzsch U, Vacca G, Dück R, Gillissen A. Anti-inflammatory effects of Myrtol tandardized and other essential oils on alveolar macrophages from patients with chronic obstructive pulmonary disease. Eur J Med Res, 2009, 14(Suppl 4): 205–209.Rantzsch U, Vacca G, Dück R, Gillissen A. Anti-inflammatory effects of Myrtol tandardized and other essential oils on alveolar macrophages from patients with chronic obstructive pulmonary disease. Eur J Med Res, 2009, 14(Suppl 4): 205–209.Cao L, Chen Y, Zhao Y, Zhang H, Wang S, Wang Z, et al. Effect of Myrtol standardized on mucus hypersecretion and clearance of Pseudomonas aeruginosa in a rat model of chronic obstructive pulmonary disease. Arzneimittelforschung, 2011, 61: 685–692.Cao L, Chen Y, Zhao Y, Zhang H, Wang S, Wang Z, et al. Effect of Myrtol standardized on mucus hypersecretion and clearance of Pseudomonas aeruginosa in a rat model of chronic obstructive pulmonary disease. Arzneimittelforschung, 2011, 61: 685–692.Ulmer WT, Schött D. Chronic obstructive bronchitis. Effect of Gelomyrtol forte in a placebo-controlled double-blind study. Fortschr Med, 1991, 109: 547–550.Ulmer WT, Schött D. Chronic obstructive bronchitis. Effect of Gelomyrtol forte in a placebo-controlled double-blind study. Fortschr Med, 1991, 109: 547–550.Hua ZQ, Chang YJ. Clinical study of decoction of invigorating Qi and clearing lung combined standardized myrtol on acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Zhongguo Zhong Yao Za Zhi, 2013, 38: 440–442.Hua ZQ, Chang YJ. Clinical study of decoction of invigorating Qi and clearing lung combined standardized myrtol on acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Zhongguo Zhong Yao Za Zhi, 2013, 38: 440–442.Sengespeik HC, Zimmermann T, Peiske C, de Mey C. Myrtol standardized in the treatment of acute and chronic respiratory infections in children. A multicenter post-marketing surveillance study. Arzneimittelforschung, 1998, 48: 990–994.Sengespeik HC, Zimmermann T, Peiske C, de Mey C. Myrtol standardized in the treatment of acute and chronic respiratory infections in children. A multicenter post-marketing surveillance study. Arzneimittelforschung, 1998, 48: 990–994.Карпова Е.П., Тулупов Д.А., Емельянова М.П. Возможности Миртола стандартизированного в терапии острого риносинусита у детей. Вестник оториноларингологии, 2016, 81(1): 47-50.Карпова Е.П., Тулупов Д.А., Емельянова М.П. Возможности Миртола стандартизированного в терапии острого риносинусита у детей. Вестник оториноларингологии, 2016, 81(1): 47-50.Кунельская Н.Л. и др. Муколитическая терапия острых и хронических риносинуситов. Медицинский совет, 2015, 3: 8-12.Кунельская Н.Л. и др. Муколитическая терапия острых и хронических риносинуситов. Медицинский совет, 2015, 3: 8-12.Овчинников А.Ю., Эдже М.А., Хон Е.Н., Коростелев С.А. Острый риносинусит: основные заблуждения и возможности стандартизированной терапии. Медицинский совет, 2016, 6: 28-31.Овчинников А.Ю., Эдже М.А., Хон Е.Н., Коростелев С.А. Острый риносинусит: основные заблуждения и возможности стандартизированной терапии. Медицинский совет, 2016, 6: 28-31.Зырянова К.С., Белошангин А.С., Коркмазов М.Ю. и др. Применение фитотерапевтического лекарственного препарата в лечении и профилактике острых риносинуситов у детей г. Челябинска. Педиатрический вестник Южного Урала, 2016, 1: 49-53.Зырянова К.С., Белошангин А.С., Коркмазов М.Ю. и др. Применение фитотерапевтического лекарственного препарата в лечении и профилактике острых риносинуситов у детей г. Челябинска. Педиатрический вестник Южного Урала, 2016, 1: 49-53.

The authors declare that there are no conflicts of interest present.